GH Research (FRA:1KA) OCF Margin %: 0.00% (As of Mar. 2026)


FRA:1KA GH Research PLC FRA:1KA
35 GF Score
Price €21.20
! 2 Warning Signs
View Full Analysis

What is GH Research OCF Margin %?

GH Research FRA:1KA +6.00% 35 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:1KA with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, GH Research ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. GH Research's Cash Flow from Operations for the three months ended in Mar. 2026 was €-9.23 Mil. GH Research's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, GH Research's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, GH Research's current OCF Yield % is -2.62%.

The historical rank and industry rank for GH Research's OCF Margin % or its related term are showing as below:


FRA:1KA's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

GH Research OCF Margin % Related Terms

GH Research OCF Margin % Historical Data

* Premium members only.

The historical data trend for GH Research's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GH Research OCF Margin % Chart

GH Research Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

GH Research Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:1KA
35GF Score
GH Research PLC FRA:1KA
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GH Research OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

GH Research's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-37.193/0
= %

GH Research's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-9.229/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
GH Research (FRA:1KA) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on GH Research and its competitors. According to the industry distribution chart, GH Research ranks #999999 out of 959 companies in the Biotechnology industry.
Is GH Research's OCF Margin % too high?
GH Research's current OCF Margin % is 0.00%. Based on the distribution chart, GH Research ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GH Research has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does GH Research's OCF Margin % compare to BHVN and NUVB?
According to the Biotechnology industry distribution chart, GH Research ranks #999999 out of 959 companies for OCF Margin %. This places GH Research in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on GH Research and its competitors. GH Research's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GH Research stock overvalued right now?
GH Research (FRA:1KA) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. GH Research's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For GH Research (FRA:1KA), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GH Research Business Description

Other Exchanges GHRS:USA
Address Dawson Street, Joshua Dawson House, Dublin 2, IRL, D02 RY95
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
35GF Score

Get the complete analysis for FRA:1KA

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.20
Price